SK719789A3 - Xantine derivatives, method for producing thereof, pharmaceutical composition containing them and their use - Google Patents

Xantine derivatives, method for producing thereof, pharmaceutical composition containing them and their use Download PDF

Info

Publication number
SK719789A3
SK719789A3 SK7197-89A SK719789A SK719789A3 SK 719789 A3 SK719789 A3 SK 719789A3 SK 719789 A SK719789 A SK 719789A SK 719789 A3 SK719789 A3 SK 719789A3
Authority
SK
Slovakia
Prior art keywords
alkyl
formula
substd
opt
compound
Prior art date
Application number
SK7197-89A
Other languages
English (en)
Slovak (sk)
Other versions
SK279525B6 (sk
Inventor
Ulrike Kufner-Muhl
Karl-Heinz Weber
Gerhard Walther
Werner Stransky
Helmut Ensinger
Gunter Schingnitz
Franz J Kuhn
Erich Lehr
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Publication of SK279525B6 publication Critical patent/SK279525B6/sk
Publication of SK719789A3 publication Critical patent/SK719789A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SK7197-89A 1988-12-22 1989-12-19 Xantine derivatives, method for producing thereof, pharmaceutical composition containing them and their use SK719789A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3843117A DE3843117A1 (de) 1988-12-22 1988-12-22 Neue xanthinderivate mit adenosin-antagonistischer wirkung

Publications (2)

Publication Number Publication Date
SK279525B6 SK279525B6 (sk) 1998-12-02
SK719789A3 true SK719789A3 (en) 1998-12-02

Family

ID=6369764

Family Applications (1)

Application Number Title Priority Date Filing Date
SK7197-89A SK719789A3 (en) 1988-12-22 1989-12-19 Xantine derivatives, method for producing thereof, pharmaceutical composition containing them and their use

Country Status (32)

Country Link
US (4) US5175291A (fr)
EP (1) EP0374808B1 (fr)
JP (1) JP2565576B2 (fr)
KR (1) KR0165666B1 (fr)
AT (1) ATE136897T1 (fr)
BG (1) BG61669B2 (fr)
BR (1) BR1100527A (fr)
CA (1) CA2006387C (fr)
CZ (1) CZ286230B6 (fr)
DD (1) DD290421A5 (fr)
DE (3) DE3843117A1 (fr)
DK (1) DK652689A (fr)
ES (1) ES2086313T3 (fr)
FI (1) FI96513C (fr)
GR (1) GR3019733T3 (fr)
HR (1) HRP940724A2 (fr)
HU (1) HU218674B (fr)
IE (1) IE74205B1 (fr)
IL (1) IL92829A (fr)
MX (1) MX9203618A (fr)
NO (1) NO173502C (fr)
NZ (1) NZ231901A (fr)
PH (2) PH31107A (fr)
PL (1) PL162877B1 (fr)
PT (1) PT92658B (fr)
RU (1) RU2057752C1 (fr)
SG (1) SG46380A1 (fr)
SI (1) SI8912423B (fr)
SK (1) SK719789A3 (fr)
UA (1) UA26427A (fr)
YU (1) YU47934B (fr)
ZA (1) ZA899881B (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
EP0459702A1 (fr) * 1990-05-29 1991-12-04 Zeneca Limited Dérivés d'azoles
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
CA2061544A1 (fr) * 1991-02-25 1992-08-26 Fumio Suzuki Composes de la xanthine
GB9111130D0 (en) * 1991-05-23 1991-07-17 Ici Plc Azole derivatives
GB9111131D0 (en) * 1991-05-23 1991-07-17 Ici Plc Heterocyclic compounds
DE69229257D1 (de) * 1991-11-08 1999-07-01 Kyowa Hakko Kogyo Kk Xanthinderivate zur Behandlung der Demenz
IT1260444B (it) * 1992-01-24 1996-04-09 Mario Brufani Derivati della 8-(1-amminocicloalchil)1,3-dialchilxantina, procedimenbto di preparazione e loro composizioni farmaceutiche antidepressive, nootropiche e psicostimolanti
EP0556778A3 (en) * 1992-02-17 1993-11-24 Kyowa Hakko Kogyo Kk Xanthine derivatives
CA2093403C (fr) * 1992-04-08 1999-08-10 Fumio Suzuki Agent de traitement de la maladie de parkinson
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
WO1994003173A1 (fr) * 1992-08-01 1994-02-17 Boehringer Ingelheim Kg Utilisation de 8-(3-oxocyclopentyle)-1,3-dipropyle-7h-purine-2,6-dione pour le traitement symptomatique de la fibrose cystique
TW252044B (fr) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
US5877179A (en) * 1992-09-29 1999-03-02 The United States Of America As Represented By The Department Of Health And Human Services Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells
DE4236331A1 (de) * 1992-10-28 1994-05-05 Boehringer Ingelheim Kg Synergistische Kombination
AU6087894A (en) * 1993-01-14 1994-08-15 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
DE69412073T2 (de) * 1993-02-26 1999-02-18 Merrell Pharmaceuticals Inc., Cincinnati, Ohio Xanthinderivate als adenosin-a1 rezeptor antagonisten
WO1994025462A1 (fr) * 1993-05-03 1994-11-10 The United States Of America, Represented By The Derives de 1,3,7-trialkyl-xanthine substitues en position 8 utiles comme antagonistes de recepteurs d'adenosine a2 a selectivite
DE4316576A1 (de) * 1993-05-18 1994-11-24 Boehringer Ingelheim Kg Verbessertes Verfahren zur Herstellung von 1,3-Dipropyl-8-(3-Oxocyclopentyl)-xanthin
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
JP3769737B2 (ja) * 1994-03-30 2006-04-26 味の素株式会社 シクロプロパン誘導体及びその製造法
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
AU4527896A (en) * 1994-12-13 1996-07-03 Euro-Celtique S.A. Aryl thioxanthines
ATE247655T1 (de) * 1994-12-13 2003-09-15 Euro Celtique Sa Dreifachsubstituierte thioxanthine
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
US5786360A (en) 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
DE69834500T2 (de) * 1997-09-05 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. Xanthinderivative zur behandlung von hirnischämie
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6521656B1 (en) * 1998-06-01 2003-02-18 Fujisawa Pharmaceutical Co., Ltd. Remedies for male sterility
CA2336967C (fr) 1998-07-10 2010-06-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Antagonistes du recepteur de l'adenosine a3
US6025362A (en) * 1998-08-31 2000-02-15 Fukunaga; Atsuo F. Uses of xanthine compounds
US6576619B2 (en) 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
EP1775297A3 (fr) * 1999-11-12 2008-12-03 Biogen Idec MA Inc. Antagonistes du récepteur de l'adénosine et leurs techniques de préparation et d'utilisation
CZ20021614A3 (cs) * 1999-11-12 2002-07-17 Biogen, Inc. Polycykloalkylpuriny jako antagonisty adenosinového receptoru
ATE336492T1 (de) 2000-01-14 2006-09-15 Us Gov Health & Human Serv Methonocarbacycloalkylanaloga von nucleosiden
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
IL161867A0 (en) 2001-11-09 2005-11-20 Cv Therapeutics Inc A2b adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) * 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
AU2003261206A1 (en) * 2002-07-19 2004-02-09 Aryx Therapeutics Xanthine derivatives having adenosine a1-receptor antagonist properties
US7202252B2 (en) * 2003-02-19 2007-04-10 Endacea, Inc. A1 adenosine receptor antagonists
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
NZ543109A (en) * 2003-04-25 2008-06-30 Novacardia Inc Method of improved diuresis in individuals with impaired renal function
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
JP2006515316A (ja) * 2003-05-06 2006-05-25 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ｂアデノシンレセプターアンタゴニストであるキサンチン誘導体
CA2528385C (fr) * 2003-06-06 2011-03-15 Endacea, Inc. Antagonistes du recepteur d'adenosine a1
WO2004110379A2 (fr) * 2003-06-09 2004-12-23 Endacea, Inc. Antagonistes de recepteur d'adenosine a1
TW200507882A (en) * 2003-07-17 2005-03-01 Kyowa Hakko Kogyo Kk Solid formulations
US6847249B1 (en) * 2003-10-09 2005-01-25 Analog Devices, Inc. Highest available voltage selector circuit
US20050239759A1 (en) * 2004-04-16 2005-10-27 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist and an aldosterone inhibitor
RS52455B (en) * 2004-09-01 2013-02-28 Gilead Sciences Inc. WALL HEALING PROCEDURE BY ADENOSINE A2B RECEPTOR ANTAGONISTS
CN101466383A (zh) * 2006-06-16 2009-06-24 美国诺华卡迪亚公司 包含低频率投与aa1ra的肾功能延长改善
US8193200B2 (en) 2007-01-04 2012-06-05 University Of Virginia Patent Foundation Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
US20080242684A1 (en) * 2007-03-29 2008-10-02 Howard Dittrich Methods of administration of adenosine a1 receptor antagonists
EP2268641B1 (fr) * 2008-03-26 2014-09-03 Advinus Therapeutics Pvt. Ltd. Composés hétérocycliques utiles comme antagonistes des récepteurs adénosiniques
US8129862B2 (en) * 2009-10-23 2012-03-06 Analog Devices, Inc. Scalable highest available voltage selector circuit
JP5843778B2 (ja) * 2009-11-09 2016-01-13 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物、その調製およびその使用
WO2011068978A1 (fr) 2009-12-02 2011-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dérivés de méthanocarba-adénosine et conjugués de dendrimère de ceux-ci

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1201997A (en) * 1967-08-04 1970-08-12 Yissum Res Dev Co New substituted purines and purine derivatives
US3624216A (en) * 1970-06-25 1971-11-30 Abbott Lab 8-substituted theophyllines as anti-inflammatory agents
US3624215A (en) * 1970-06-25 1971-11-30 Abbott Lab 8-substituted theophyllines as anti-anxiety agents
DE3028273A1 (de) * 1980-07-25 1982-02-25 Fa. Dr. Willmar Schwabe, 7500 Karlsruhe Durch purinbasen substituierte 1.4;3.6-dianhydro-hexit-nitrate
ES517622A0 (es) * 1982-11-23 1983-12-16 Faes Procedimiento de preparacion de un nuevo espirodecano.
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4548939A (en) * 1984-10-01 1985-10-22 Janssen Pharmaceutica N. V. 1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones
US4755517A (en) * 1986-07-31 1988-07-05 Warner-Lambert Company Derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US5175290A (en) * 1988-09-16 1992-12-29 Marion Merrell Dow Inc. 8-(oxo-substituted cycloalkyl)xanthines
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US4957921A (en) * 1989-12-06 1990-09-18 Warner-Lambert Company Substituted cyclohexanols as central nervous system agents
DE69229257D1 (de) * 1991-11-08 1999-07-01 Kyowa Hakko Kogyo Kk Xanthinderivate zur Behandlung der Demenz

Also Published As

Publication number Publication date
HU896736D0 (en) 1990-02-28
PL162877B1 (pl) 1994-01-31
ATE136897T1 (de) 1996-05-15
BR1100527A (pt) 2000-08-01
UA26427A (uk) 1999-08-30
PL282878A1 (en) 1992-03-09
HU218674B (hu) 2000-10-28
DD290421A5 (de) 1991-05-29
NO895168D0 (no) 1989-12-21
GR3019733T3 (en) 1996-07-31
BG61669B2 (bg) 1998-02-27
DE58909657D1 (de) 1996-05-23
NO895168L (no) 1990-06-25
RU2057752C1 (ru) 1996-04-10
ES2086313T3 (es) 1996-07-01
PH31111A (en) 1998-02-23
CZ286230B6 (cs) 2000-02-16
HRP940724A2 (en) 1997-06-30
SK279525B6 (sk) 1998-12-02
ZA899881B (en) 1991-08-28
PT92658B (pt) 1995-09-12
JPH02247180A (ja) 1990-10-02
IL92829A0 (en) 1990-09-17
KR900009646A (ko) 1990-07-05
HUT52503A (en) 1990-07-28
MX9203618A (es) 1992-09-01
YU47934B (sh) 1996-05-20
DE8817122U1 (de) 1993-02-04
IE74205B1 (en) 1997-07-16
DE3843117A1 (de) 1990-06-28
NZ231901A (en) 1993-12-23
CA2006387C (fr) 2000-02-08
US5688802A (en) 1997-11-18
US5532368A (en) 1996-07-02
SG46380A1 (en) 1998-02-20
IE894147L (en) 1990-06-22
FI96513B (fi) 1996-03-29
EP0374808A3 (fr) 1991-05-15
SI8912423B (sl) 1998-12-31
FI96513C (fi) 1996-07-10
YU242389A (en) 1991-10-31
US5175291A (en) 1992-12-29
US5696124A (en) 1997-12-09
PT92658A (pt) 1990-06-29
EP0374808A2 (fr) 1990-06-27
FI896117A0 (fi) 1989-12-20
EP0374808B1 (fr) 1996-04-17
CA2006387A1 (fr) 1990-06-22
CZ719789A3 (cs) 1999-10-13
PH31107A (en) 1998-02-23
SI8912423A (sl) 1998-04-30
DK652689D0 (da) 1989-12-21
NO173502B (no) 1993-09-13
AU4707289A (en) 1990-06-28
JP2565576B2 (ja) 1996-12-18
IL92829A (en) 1995-12-31
AU637990B2 (en) 1993-06-17
NO173502C (no) 1993-12-22
DK652689A (da) 1990-06-23
KR0165666B1 (ko) 1999-01-15

Similar Documents

Publication Publication Date Title
SK719789A3 (en) Xantine derivatives, method for producing thereof, pharmaceutical composition containing them and their use
US5641784A (en) 8-substituted 1,3-dialiphaticxanthine derivatives
US4201860A (en) Purine derivatives
EP0759921B1 (fr) Procede de preparation de derives azabicycliques
US4172829A (en) 2,9-Disubstituted adenine derivatives and their use as non-adrenergic bronchodilators
CA1252086A (fr) Derives de pyrazole ayant la structure moleculaire de l'ergoline, sels d'addition acide desdits derives et procede de preparation
US4381305A (en) Ethylenediamine derivatives and pharmaceutical compositions containing same
CA1254208A (fr) 3,7-diazabicyclo¬3.3.1|nonanes et leur preparation
US4232155A (en) Purine compounds
US4826975A (en) Fused cycloaliphatic aminoalcohols
JPS6072879A (ja) ７−オキサビシクロヘプタン置換チオカルバメ−トプロスタグランジン類縁体
JPH02289581A (ja) 光学的に純粋なヘトラゼピン類の改良された製造方法
US4410526A (en) Oxazolidin-2-one prostaglandin compounds
JPH0530835B2 (fr)
US4269839A (en) Alkylthio-adenines used as bronchodilators
JPS6229568A (ja) メチル−９−オキソ−１１α，１６−ジヒドロキシ−１６−ビニル−５−シス−１３−トランス−プロスタジエノエ−ト類の前駆物質及び合成法
DK145906B (da) Analogifremgangsmaade til fremstilling af n,n-dimethyl-trans-2-(m-halogenphenyl)bicyclo(2,2,2)oct-3-yl-methylamin og syreadditionssalte deraf
FR2463142A1 (fr) Nouveaux composes de purine, leur procede de production et composition pharmaceutique les contenant
NO122834B (fr)